While all intrinsic molecular subtypes have been observed among clinically HER2+ breast cancers defined by traditional IHC/FISH criteria, the majority (67%) are classified as HER2-enriched, with ER-positive (ER+)/HER2+ cases being HER2-enriched 54% of the time [8]. This evidence concerns the gene ESR1 and breast cancer.